We all know that before Healey is the go, the FDA hold needs to be lifted (3QCY2025) and once thats behind us its reasonable to expect the SP will be up significantly and investor interest including BP will be piqued. The last CR price of 19 cents will be a thing of the past, a distant memory in the revision mirror.
It's not unreasonable to assume with Healey on the horizon and additional shots on goal (neurodegenerative diseases) the raising of cash through non dilutive financing and or an equity issuance would not be a problem. The lifting of the hold will be a significant and major price sensitive event and one watched by the serious investors/BP. The appointment of a CFO and having him as a traveling team member = chasing down funding opportunities and/or dealing with M&A proposals all of which are probably contingent on the lifting of the hold and pre-clinical results.
BTW AUD50 million = ~USD32 million. USD32 million is not an unusual up front fee by BP for a finger in NUZ's pie once all impediments for entry to Healey are overcome. No need for Vegas' and Monaco's funny money when the real deal is there for the taking.
NUZ Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)